PAKUP·AIdownload ⇩▶ studio
compare
REPORT · JNJ v1· ARCHIVED
PAKUP·AI
LIVING REPORT · REPORT NO. 1
v1 · 2026-08-14
ARCHIVED VERSION

Johnson & Johnson $260.35 -0.66%

stock · data as of 2026-08-14 · computed, sourced, never predicted
00Executive summary

Johnson & Johnson closed at $260.35 (-0.66% on the day). Over the last month it is +4.15%, over the last year +53%. It sits 2.58% below the 52-week high of $267.24 (52-week low $170.17).

Price holds above both the 50-day and 200-day averages — the market's own trend vote is constructive on both horizons.

latest change — first committed version3 invalidation conditions stated — section 07
01What changed — v1
  • · first committed version — nothing to diff against yet
02Technicals

Johnson & Johnson closed at $260.35 (-0.66% on the day). Over the last month it is +4.15%, over the last year +53%. It sits 2.58% below the 52-week high of $267.24 (52-week low $170.17).

Trend: price is ABOVE the 200-day average ($228.3) and above the 50-day ($251.31) — trend strength (R², 90d) 0.67, direction sideways.

Volatility: 30-day realized vol is 22.65% annualized, the 82th percentile of this asset's own history — a loud tape. Short-horizon behavior leans no clear_bias.

Structure (90 days): range $220.05 – $267.24; the most-touched level is $224.88 (26 touches).

1W
+0.43%
1M
+4.15%
1Y
+53%
FROM 52W HIGH
-2.58%
03Fundamentals

Fundamentals (latest annual filing, 2025-12-28): revenue $94.19B (+6.05% YoY), gross margin 67.88%, operating margin 22.92%, net margin 28.46%, ROE 31.54%, ROIC 20.15% (EBIT basis), operating cash flow $24.53B, free cash flow $19.7B (3.14% yield), net debt position $22.19B (0.51 debt/equity), trailing P/E on annual diluted EPS: 23.6, revenue CAGR over the last 5 completed fiscal years: 44.64%. Source: SEC EDGAR.

REVENUE
$94.19B
REVENUE YOY
+6.05%
NET INCOME
$26.8B
NET MARGIN
28.46%
EPS (DILUTED)
$11.03
TRAILING P/E
23.6
04Sentiment

The tape leans neutral: 52% of the last 90 sessions closed up, direction sideways, short-horizon behavior no clear bias.

Positioning: 1.32 standard deviations above the 90-day mean, 2.58% from the all-time high of this series.

computed from price action, not from opinions or positioning surveys

05Consensus read

Price holds above both the 50-day and 200-day averages — the market's own trend vote is constructive on both horizons.

The 1-month move (+4.15%) agrees with the 1-year trend (+53%).

Trading within 2.58% of the 52-week high — priced near its best.

analyst-rating feeds are licensed; this section reads the market's own positioning instead

06In the air — headlines, not causes
  • · 5 Dividend Aristocrats to Buy for Lifelong Income in August 247wallst.com · 4h ago
  • · This Dividend Aristocrat Posted Record Quarterly Results finance.yahoo.com · 39h ago
  • · Johnson & Johnson (JNJ) Stock Looks Cheap On Cash Flow But Rich On Earnings finance.yahoo.com · 44h ago
  • · Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report? finance.yahoo.com · 47h ago
  • · 5 Dividend Kings to Buy and Hold Forever in August 247wallst.com · 52h ago
  • · Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief? finance.yahoo.com · 64h ago
  • · Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually. fool.com · 68h ago
  • · AbbVie Defends Its Turf, But Leaves One Big Question Open trefis.com · 41h ago
  • · Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026? finance.yahoo.com · 45h ago
  • · 3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold finance.yahoo.com · 49h ago
07What would change this read
  • · The trend read flips on a daily close below the 200-day average at $228.3.
  • · The volatility read changes if realized vol leaves its current regime (now the 82th percentile).
  • · The fundamental read updates on the next 10-K/10-Q filing — annual figures can be three quarters stale between filings.
  • · nothing here is a prediction or advice — it is a computed description of end-of-day data
$260.35-0.66%CONSTRUCTIVE